Empagliflozin selected cardiovascular and safety outcomes in routine care: First results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

被引：0
|
作者：
Patorno, E. [1 ]
Pawar, A. [1 ]
Franklin, J. M. [1 ]
Najafzadeh, M. [1 ]
Deruaz-Luyet, A. [2 ]
Brodovicz, K. G. [3 ]
Sambevski, S. [4 ]
Bessette, L. G. [1 ]
Kulldorff, M. [1 ]
Schneeweiss, S. [1 ]
机构：
[1] Harvard Med Sch, Div Pharmacoepidemiol, Dept Med, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Boehringer Ingelheim Int GmbH, Corp Dept Global Epidemiol, Ingelheim, Germany
[3] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[4] Boehringer Ingelheim Int GmbH, Corp Dept Med, Ingelheim, Germany
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2020年 / 104卷
关键词：
Sodium glucose co-transport inhibitor 2; Healthcare utilization; Diabetic ketoacidosis;
D O I：
10.1016/j.metabol.2019.12.072
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] CARDIOVASCULAR EFFECTIVENESS OF EMPAGLIFLOZIN COMPARED TO DPP4I IN ROUTINE CARE IN EAST ASIA: RESULTS FROM THE EMPRISE STUDY
    Kim, Dae Jung
    Sheu, Wayne H-H
    Chung, Wook-Jin
    Yabe, Daisuke
    Ha, Kyoung Hwa
    Tan, Elise Chia-Hui
    Taneda, Yusuke
    Lei, Vanessa
    Saarelainen, Laura
    Deruaz-Luyet, Anouk
    Kyaw, Moe H.
    Seino, Yutaka
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 542 - 542
  • [32] Cardiovascular Effectiveness of Empagliflozin Compared to DPP4 Inhibitors and to GLP1 Receptor Agonists: Interim Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica
    Najafzadeh, Mehdi
    Wexler, Deborah
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Bessette, Lily
    Schneeweiss, Sebastian
    CIRCULATION, 2019, 140
  • [33] Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
    Dorte Vistisen
    Bendix Carstensen
    Patorno Elisabetta
    Stefanie Lanzinger
    Elise Chia-Hui Tan
    Daisuke Yabe
    Dae Jung Kim
    Wayne H.-H. Sheu
    Cheli Melzer-Cohen
    Reinhard W. Holl
    Júlio Núñez
    Kyoung Hwa Ha
    Sigrun Halvorsen
    Gisle Langslet
    Avraham Karasik
    Thomas Nyström
    Leo Niskanen
    Sonia Guleria
    Riho Klement
    Marc Carrasco
    Johannes Foersch
    Christina Shay
    Lisette Koeneman
    Fabian Hoti
    Soulmaz Fazeli Farsani
    Kamlesh Khunti
    Francesco Zaccardi
    Anuradhaa Subramanian
    Krishnarajah Nirantharakumar
    Cardiovascular Diabetology, 22
  • [34] Cardiovascular Effectiveness of Empagliflozin Compared to Glucagon Like Peptide-1 Receptor Agonists and to Dipeptidyl Peptidase-4 Inhibitors in Older Patients: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Htoo, Phyo
    Paik, Julie
    Tesfaye, Helen
    Schneeweiss, Sebastian
    Jawaid, Dureshahwar
    Wexler, Deborah
    Glynn, Robert
    Koeneman, Lisette
    Luyet, Anouk Deruaz
    Najafzadeh, Mehdi
    Patorno, Elisabetta
    CIRCULATION, 2021, 144
  • [35] Healthcare Resource Utilization Among Empagliflozin Initiators With and Without Cardiovascular Disease versus DPP4i in a Commercially-Insured Routine Care Population: An Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
    Najafzadeh, Mehdi
    Pawar, Ajinkya
    Schneeweiss, Sebastian
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly
    Ustyugova, Anastasia
    Gautam, Nileesa
    Patorno, Elisabetta
    CIRCULATION, 2019, 140
  • [36] COMPARATIVE HEALTHCARE COSTS AND MEDICATION BURDEN IN REAL-WORLD PATIENTS AUGMENTING METFORMIN MONOTHERAPY WITH EMPAGLIFLOZIN FROM THE EMPAGLIFLOZIN COMPARATIVE EFFECTIVENESS AND SAFETY (EMPRISE) STUDY
    Pawar, A.
    Patorno, E.
    Deruaz-Luyet, A.
    Brodovicz, K. G.
    Ustyugova, A.
    Bessette, L. G.
    Ortiz, Santiago A. J.
    Schneeweiss, S.
    Najafzadeh, M.
    VALUE IN HEALTH, 2019, 22 : S161 - S161
  • [37] Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care A First Analysis From the EMPRISE Study
    Patorno, Elisabetta
    Pawar, Ajinkya
    Franklin, Jessica M.
    Najafzadeh, Mehdi
    Deruaz-Luyet, Anouk
    Brodovicz, Kimberly G.
    Sambevski, Steven
    Bessette, Lily G.
    Ortiz, Adrian J. Santiago
    Kulldorff, Martin
    Schneeweiss, Sebastian
    CIRCULATION, 2019, 139 (25) : 2822 - 2830
  • [38] Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study (vol 4, e00181, 2021)
    Yutaka, S.
    Dae, J. K.
    Daisuke, Y.
    ENDOCRINOLOGY DIABETES & METABOLISM, 2023,
  • [39] Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study
    Kim, Dae Jung
    Sheu, Wayne H-H
    Chung, Wook-Jin
    Yabe, Daisuke
    Ha, Kyoung Hwa
    Nangaku, Masaomi
    Tan, Elise Chia-Hui
    Node, Koichi
    Yasui, Atsutaka
    Lei, Weiyu
    Lee, Sunwoo
    Saarelainen, Laura
    Deruaz-Luyet, Anouk
    Kyaw, Moe H.
    Seino, Yutaka
    EMPRISE East Asia Study Grp
    JOURNAL OF DIABETES INVESTIGATION, 2023, 14 (03) : 417 - 428
  • [40] Comparative effectiveness and safety of empagliflozin on cardiovascular mortality and morbidity in adults with type 2 diabetes
    Aronow, Wilbert S.
    Shamliyan, Tatyana A.
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (23)
12345